Brainstorm Cell Therapeutics Inc BCLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.82
- Day Range
- $0.77–0.80
- 52-Week Range
- $0.46–1.69
- Bid/Ask
- $0.77 / $0.80
- Shares Outstanding
- 11.03M
- Market Cap
- $8.85M
- Volume/Avg
- 4,414 / 21,040
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.brainstorm-cell.com
Valuation
|
Metric
|
BCLI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BCLI
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.03 |
Interest Coverage | −17.40 |
Quick Ratio
BCLI
Profitability
|
Metric
|
BCLI
|
|---|---|
Return on Assets (Normalized) | −602.44% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BCLI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|l^D<fD | LOCK|!ln$ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?PWvqz | LOCK|?$!b | $83B | |||
| Moderna Inc
MRNA
| LOCK|rDGf@nH | LOCK|M^ | $80B | |||
| argenx SE ADR
ARGX
| LOCK|N!cRm% | LOCK|y? | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FNCy^@ | LOCK|G>b | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@$#ptH< | LOCK|TDX$^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$Z@LZR@l | LOCK|@MxV | $28B | |||
| Incyte Corp
INCY
| LOCK|?MZ#&n | LOCK|yR? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|y?DT#r< | LOCK|f& | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|S?d?>& | LOCK|&$ | $14B |
United States